DrugDashboards

Potassium Citrate

potassium citrate · POTASSIUM CITRATE 15 meq/1 · Tablet · Oral · Biocomp Pharma, Inc.

NDC 44523-0415-01 · 100 TABLET in 1 BOTTLE · NDA AUTHORIZED GENERIC · View full market →

The short version

4 companies supply this market — a reasonable cushion if one runs into trouble. The generic price is down 17% over the past year, to $0.1804 per unit. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$0.1804per EAinvoice-surveyed acquisition cost · Aug 19, 2026
  • Part D plans paid (avg)$0.6062per dosage unitgross, before rebates — matched by drug name · 2024
  • Federal ceiling (Big4)$0.1131per unitMission Pharmacal Company · Jan 1, 202663% of what pharmacies pay — a deeper discount than 81% of drugs with this benchmark
  • Medicaid generic ceiling (FUL)$0.1804per TABweighted avg manufacturer price $0.0793 · Aug 1, 2026100% of what pharmacies pay — higher than 10% of drugs with this benchmark

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 42543-0408-01) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$0.5233per unit
middle half $0.3372$0.8493 · 5,455 plans · Apr 1, 2026
Est. net of rebates
≈ $0.5233
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
99%of plans cover it
tier 3 · prior auth 0% · step therapy 0% · qty limit 0%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

$0$1.00$2.00$3.00Apr 2014Sep 2026$0.1804
150 price points · per EA · dashed = manufacturer avg (WAMP)Source: CMS NADAC

Estimated fill cost

#30 count
$5.41
#90 count
$16.24

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Medicaid spend (2025)

$74,398
2,855 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

5Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • 4 active manufacturers+5

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for potassium citrate (oral solid) in the next 90 days

sole-source market · price up 1% YoY

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $94.21 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program · Xywav and Xyrem

Regulatory

Application
NDA019071
TE code
AB
Approval date
Aug 30, 1985
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of potassium citrate (Tablet)

LabelerStrengthFirst seenLast seen
Bryant Ranch PrepackPOTASSIUM CITRATE 10 meq/1Jul 15, 2026Sep 3, 2026
Biocomp Pharma, Inc.POTASSIUM CITRATE 15 meq/1Jul 15, 2026Sep 2, 2026
Biocomp Pharma, Inc.POTASSIUM CITRATE 10 meq/1Jul 15, 2026Sep 2, 2026
Bryant Ranch PrepackPOTASSIUM CITRATE 15 meq/1Jul 15, 2026Sep 2, 2026
Bryant Ranch PrepackPOTASSIUM CITRATE 5 meq/1Jul 15, 2026Sep 2, 2026
Strides Pharma Inc.POTASSIUM CITRATE 10 meq/1Jul 15, 2026Sep 2, 2026
Strides Pharma Inc.POTASSIUM CITRATE 15 meq/1Jul 15, 2026Sep 2, 2026
Strides Pharma Inc.POTASSIUM CITRATE 5 meq/1Jul 15, 2026Sep 2, 2026
Upsher-Smith Laboratories, LLCPOTASSIUM CITRATE 5 meq/1Jul 15, 2026Sep 2, 2026
Upsher-Smith Laboratories, LLCPOTASSIUM CITRATE 10 meq/1Jul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Potassium Citrate — NDC 44523-0415-01," retrieved September 3, 2026, https://drugdashboards.com/drug/44523041501.

Free to cite with attribution — see how the data is put together.